PolyPid Ltd. (NASDAQ:PYPD – Get Rating) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 114,900 shares, a decline of 45.0% from the April 30th total of 209,000 shares. Based on an average daily volume of 98,800 shares, the days-to-cover ratio is currently 1.2 days.
PolyPid Stock Performance
Shares of PYPD stock opened at $0.38 on Friday. The firm has a fifty day simple moving average of $0.42 and a two-hundred day simple moving average of $0.64. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.75 and a current ratio of 2.75. PolyPid has a 12 month low of $0.33 and a 12 month high of $6.90.
PolyPid (NASDAQ:PYPD – Get Rating) last announced its quarterly earnings results on Wednesday, May 10th. The company reported ($0.28) EPS for the quarter. Analysts expect that PolyPid will post -1.05 earnings per share for the current fiscal year.
Institutional Trading of PolyPid
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.
- Get a free copy of the StockNews.com research report on PolyPid (PYPD)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.